A mouse study suggests tirzepatide, sold as Mounjaro and Zepbound, may activate calorie-burning brown fat, offering a new understanding of its metabolic benefits.
An experimental compound called TOFA helped obese mice burn fat, preserve muscle, and improve metabolic health, offering a new approach to obesity treatment.
A new oral GLP-1 drug, aleniglipron, showed significant weight loss of up to 12.1% in a 36-week trial, offering a potential alternative to injectable medications.
A six-month trial found that reducing sweet-tasting foods did not curb cravings or improve health markers for diabetes and heart disease.
A study found that 75 minutes of brisk interval walking once a week can reduce body fat and improve fitness as effectively as three weekly sessions.
A study found that eating one avocado daily may reduce heart disease risk in adults with obesity by lowering harmful LDL particle levels in the blood.
A study found that a 12-week intermittent fasting program helped overweight and obese adults sustain weight loss for at least one year after the intervention.
A new report suggests fructose may act as a metabolic trigger for obesity and chronic diseases, affecting the body differently than other sugars.
A new study reveals that hormone-sensitive lipase (HSL), a protein known for fat breakdown, also maintains fat cell health from within the nucleus, challenging previous assumptions about obesity and metabolic disease.
A fat-burning protein, hormone-sensitive lipase (HSL), has been found to control fat cell health from inside the nucleus, challenging previous obesity research.
A new "Trojan horse" drug for obesity and type two diabetes shows promise in mouse studies, delivering a metabolic enhancer directly to cells for improved weight loss and blood sugar control.